

# KEY INVESTOR INFORMATION

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

## Lyxor ESG Euro Corporate Bond (DR) UCITS ETF - Acc (the "Fund")

ISIN: LU1829219127 - A sub-fund of the investment company named MULTI UNITS LUXEMBOURG (the "Company") domiciled in Luxembourg. Managed by Lyxor International Asset Management S.A.S. ("LIAM")

### Objectives and investment policy

The Fund is an index-tracking UCITS passively managed. The investment objective of the Fund is to track both the upward and downward evolution of the Bloomberg Barclays MSCI EUR Corporate Liquid SRI Sustainable Index (the "**Benchmark Index**") denominated in Euro, while minimizing the difference between the return of the Fund and the return of the Benchmark Index (the "**Tracking Error**"). The anticipated level of Tracking Error in normal market conditions is indicated in the prospectus.

The Benchmark Index is representative of the performance of investment grade corporate bonds denominated in Euros issued by entities meeting Environmental, Social and Governance ("ESG") criteria, based on an ESG rating. The ESG rating methodology is based on ESG key issues including but not limited to water stress, carbon emissions, labor management or business ethics. The Benchmark Index uses a "Best-in-class" approach that permits the reduction by at least 20% of the Eligible Universe (expressed in number of issuers). Limits of the methodology of the Benchmark Index are described in the prospectus of the Fund through risk factors, such as the market risk linked to controversies and the risks linked to ESG methodologies and to ESG score computation.

Additional information on the Benchmark Index may be found on the following website:

<https://www.bloomberg.com/professional/product/indices/bloomberg-barclays-indices/>

The Benchmark Index is a total return index. A total return index calculates the performance of the index constituents on the basis that any coupons or distributions are included in the index returns.

The Fund seeks to achieve its objective via a direct replication, by investing primarily in the securities comprising the Benchmark Index. To optimize the Benchmark Index replication, the Fund may use a sampling replication strategy, and may also be engaged in securities lending transactions. The potential use of these techniques is published on Lyxor's website: [www.lyxoretf.com](http://www.lyxoretf.com).

Updated composition of the Fund holdings is available on [www.lyxoretf.com](http://www.lyxoretf.com).

In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the Fund, and might also be mentioned on the websites of the stock exchanges where the Fund is listed.

The share currency is the Euro (EUR).

- **Invested financial instruments:** International Bonds, FDI.
- **Dividend policy:** the Fund's amounts available for distribution (if any) shall not be distributed to Shareholders, but reinvested.
- **Net Asset Value:** is calculated daily provided that the relevant stock exchanges are open for trading and orders can be covered.
- **Redemptions:** investors are able to redeem their shares on the primary market every valuation day before 16:45 Europe/Luxembourg and sell their shares on the secondary market at any time during trading hours on the Fund listing places.

### Risk and reward profile



The risk-return category shown above is based on the historical performance of the assets included in the Fund or the performance of its benchmark index or the computed performance of a portfolio model. This risk estimate may therefore not represent a reliable indicator of future risk, and may be subject to change over time. The lowest category does not mean risk free investment. Resulting from its exposure to the Benchmark Index, the Fund has been classified within category 3. Category 3 indicates that under normal market conditions a small capital loss is possible ; the value of your investment may have slight and very low daily upside or downside variations.

Main risks not covered by the above indicator which could lead to a decrease in the net asset value of the Fund and which the Fund is authorized to disclose in this document (for more details about risks, please refer to the Risk Profile section of the prospectus):

- **Counterparty risk:** The Fund is exposed to the risk that any counterparty with which it has concluded an agreement or a transaction could become insolvent or otherwise default and more particularly when it has concluded financial derivative instruments over-the-counter or securities lending transactions. If such an event occurs, the net asset value of the Fund may decrease significantly. According to the regulation applicable to the Fund, such risk cannot exceed 10% of the Fund's total assets per counterparty.
- **Risk of Financial derivative Instruments:** The Fund invests in financial derivative instruments. These financial derivative instruments can induce different types of risks such as (but not limited to) leverage risk, high volatility risk, valuation risk or liquidity risk. If this risk occurs, the net asset value of the Fund may decrease significantly.
- **Operational risk:** In the event of an operational failure of the management company or one of its representatives, investors could experience loss, delay in processing subscriptions, conversions, redemptions orders or other type of disruptions.
- **Liquidity risk:** In certain circumstances, for example in case of low trading volume on financial markets, any buy or sale trade on financial instruments held by the Fund or having an impact on its value may lead to important variations of their valuations. In such circumstances, the net asset value of the Fund could be negatively affected.
- **Credit risk:** The Fund is subject to the risk that any issuer could become insolvent or to otherwise event having an impact on the credit quality of this issuer. The consequence of this risk or event may result in a decrease of the net asset value of the Fund.

## Charges for this Fund

The charges you pay are used to pay the costs of running the Fund including the costs of marketing and distributing it. These charges reduce the potential growth of your investment. For any additional information regarding charges, please refer to the relevant charges section of the Fund prospectus, available at [www.lyxoretf.com](http://www.lyxoretf.com).

### One-off charges taken before or after you invest

<b>Entry Charge:</b>	<b>Not Applicable for secondary market investors*</b>
<b>Exit Charge:</b>	<b>Not Applicable for secondary market investors*</b>

This is the maximum that might be taken out of your money before it is invested and before the proceeds of your investment are paid out.

**\*Secondary Market:** because the Fund is an ETF, Investors who are not Authorized Participants will generally only be able to buy or sell shares on the secondary market. Accordingly, investors will pay brokerage fees and/or transaction costs in connection with their dealings on stock exchange(s). These brokerage fees and/or transaction costs are not charged by, or payable to, the Fund nor the Management Company but to the investor own intermediary. In addition, the investors may also bear the costs of "bid-ask" spreads; meaning the difference between the prices at which shares can be bought and sold.

**Primary Market:** Authorized Participants dealing directly with the Fund will pay related primary market transaction costs.

For more information, please see the relevant sections in the Prospectus of the Fund.

### Charges taken from the Fund over a year.


<b>Ongoing charge:</b>	0.14 %.
------------------------	---------

The rate of ongoing charges shown here is an estimate of the charges. This estimate reflects the decrease in management fees effective from November 17, 2020. The figure shown here corresponds to the rate applicable after this date and will differ from the exact charges made during the whole year including the period before the change. The UCITS' annual report for each financial year will include detail on the exact charges made. It excludes performance fees and portfolio transaction costs, except in the case of an entry/exit charge paid by the Fund when buying or selling units or shares of underlying collective investment schemes.

### Charges taken from the Fund under certain specific conditions

<b>Performance fee:</b>	Not applicable.
-------------------------	-----------------

## Past performance



Past performances are not a reliable indicator of future results. The performance is disclosed in Euro (EUR) and net of all fees charged to the Fund. The Fund was created on 25 October 2018.

When the Benchmark Index is denominated in a currency other than the Fund currency, the performance of the Benchmark Index is converted into the Fund's currency for comparison purpose. FOREX transactions are executed on a daily basis (WM Reuters 5 pm rate on the relevant date).

(\*) Until 26/08/2019, the Fund's Benchmark Index was Markit iBoxx EUR Liquid Corporates 125 Mid Price TCA.

(\*) Until 16/11/2020, the performance of the Fund disclosed here correspond to an indirect replication of the Benchmark Index. From 17/11/2020, the performance of the Fund disclosed here correspond to a direct replication of the Benchmark Index.

(\*) Until 01/09/2015, the Fund's Benchmark Index was the Markit iBoxx Euro Liquid Corporate Overall Index.

(\*) Until 25/10/2018, the performance of the Fund indicated corresponds to that of the Lyxor Euro Corporate Bond UCITS ETF (the Absorbed fund). The latter was absorbed by the Fund on 25/10/2018.

## Practical information

### ■ Custodian: Société Générale Luxembourg.

Further practical information about the Fund, the latest prospectus, as well as the latest annual reports and any subsequent half yearly-report are available in French or in English, free of charge from the client servicing department of the management company, 17, Cours Valmy, Tour Société Générale 92800 Puteaux, FRANCE.

The Fund is a sub-fund of the Company MULTI UNITS LUXEMBOURG. The prospectus, as well as the latest annual reports and any subsequent half yearly-report are established for the entire Company.

Assets and liabilities of each Sub-Fund are segregated by law (i.e. assets of the Fund can not be used to pay the liabilities of other sub-funds of the Company). If applicable, conversion rules between sub-funds are detailed in the prospectus of the Company.

### ■ Additional information: the net asset value and other share class information (if any), are available on [www.lyxoretf.com](http://www.lyxoretf.com).

Information on market makers, exchanges and other trading information are available on the page dedicated to the Fund on the website [www.lyxoretf.com](http://www.lyxoretf.com). The indicative net asset value is published in real time by the exchange during trading hours.

### ■ Tax: the tax legislation applicable in the member state where the Fund is registered may have an impact on investors. Please contact your usual tax counsel for any further information.

Lyxor International Asset Management may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus of the Fund.

The details of the management company's updated remuneration policy are available at [www.lyxor.com](http://www.lyxor.com) or free of charge upon written request to the management company. This policy describes in particular the methods for calculating the remuneration and benefits of certain categories of employees, the bodies responsible for their allocation and the composition of the Compensation Committee.

The Fund is authorized in Luxembourg and supervised by the Commission de surveillance du secteur financier. Lyxor International Asset Management is regulated by the Autorité des marchés financiers.

The key investor information is accurate and up to date as at March the 10th, 2021.